Overview

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
Phase:
Phase 3
Details
Lead Sponsor:
NanoBio Corporation
Treatments:
5- ((2- (6- Amino- 9H- purin- 9- yl) ethyl) amino) - 1- pentanol
5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol